Cardium Therapeutics, Inc. (CXM) Wins IP Protection for Cardiovascular Gene Therapy
Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today announced it was on the winning side of a patent decision made in Europe. This decision resolved a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease. Cardium’s Generx® gene therapy candidate, which employs these key methods, is currently in late-stage clinical studies. Cardium’s patent portfolio now includes allowed and issued patents covering its gene therapy approach both…